Nuvectis Pharma, Inc.
NASDAQ:NVCTBiotechnology
+$0.39 today
- Market cap
- $697.75M
- Beta
- -0.07
- P/E (TTM)
- -11.2
- EPS (TTM)
- -$1.16
Volume 0.19M
Average 0.08M
NVCT Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Nuvectis Pharma, Inc.NASDAQ: NVCT
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development grows, but more slowly than its trailing trend
Q1 FY2026 research & development of $4.11M rose 11.6% year over year, behind the +33.3% change in trailing-twelve-month research & development. Sequentially, it fell 19.3% from the prior quarter. Over 3 fiscal years it compounded at +11.1% a year.
Context
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +11.6% toward the trailing-twelve-month pace of +33.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 18.15M USD
- Year-over-year change
- +40.5%
- 4-year CAGR
- +17.4%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 18.15M | +40.5% |
| FY2024 | 2024-12-31 | 12.92M | -16.0% |
| FY2023 | 2023-12-31 | 15.38M | +16.3% |
| FY2022 | 2022-12-31 | 13.23M | +38.6% |
| FY2021 | 2021-12-31 | 9.55M | — |
Research & Development vs competitors
How NVCT compares with its peers on the latest reported figures
- NVCT's LTM Mar 2026 research & development of $18.58M is the 10th highest of the 11 companies compared; the peer median is $125.66M.
- Its year-over-year change of +33.3% is the 4th highest of 11, against a peer median of +20.5%.
- Over three fiscal years its annual growth of +11.1% compares with a peer median of +22.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $10.68B | +22061.7% | +5.1% | — | |
| LTM Mar 2026 | $255.99M | +3.7% | +29.7% | 117.9% | |
| LTM Mar 2026 | $135.36M | -19.9% | -12.2% | 86.2% | |
| LTM Jun 2026 | $128.85M | +18.2% | +9.4% | 75.8% | |
| LTM Mar 2026 | $127.65M | +60.8% | +33.1% | 590.6% | |
| LTM Mar 2026 | $123.67M | +33.3% | +31.4% | 249.4% | |
| LTM Mar 2026 | $116.62M | -0.1% | +21.2% | — | |
| LTM Mar 2026 | $56.29M | +22.7% | +23.1% | — | |
| LTM Mar 2026 | $20.26M | +102.3% | +57.1% | — | |
| LTM Mar 2026 | $18.58M | +33.3% | +11.1% | — | |
| LTM Mar 2026 | $18.13M | -12.8% | -16.7% | 3625.8% | |
| Peer median (excluding NVCT) | $125.66M | +20.5% | +22.2% | 183.6% | |
Competitors are the stored peer set for NVCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 9.55M | 13.23M | 15.38M | 12.92M | 18.15M |
| Selling, General & Admin | 3.35M | 6.01M | 7.52M | 6.93M | 9.42M |
| Operating Expenses | 12.89M | 19.23M | 22.9M | 19.85M | 27.57M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| EBITDA | (12.89M) | (19.09M) | (22.26M) | (19M) | (26.44M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (12.89M) | (19.23M) | (22.9M) | (19.85M) | (27.57M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 4K | 149K | 637K | 847K | 1.13M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 4K | 149K | 637K | 847K | 1.13M |
| Income Before Tax | (12.89M) | (19.09M) | (22.26M) | (19M) | (26.44M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (12.89M) | (19.09M) | (22.26M) | (19M) | (26.44M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.09) | (1.51) | (1.43) | (1.11) | (1.32) |
| EPS (Diluted) | (1.09) | (1.51) | (1.43) | (1.11) | (1.32) |
| Weighted Avg Shares | 12.72M | 12.66M | 15.56M | 17.11M | 21.81M |
| Weighted Avg Shares (Diluted) | 12.72M | 12.66M | 15.56M | 17.11M | 21.81M |
Nuvectis Pharma, Inc.
NASDAQ:NVCT
Intrinsic Alpha fair value
Locked
Current Price
$20.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.